Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Rating of "Buy" by Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have been assigned a consensus rating of "Buy" from the ten analysts that are presently covering the company, Marketbeat Ratings reports. Ten analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $73.38.

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Jasper Therapeutics in a report on Monday, September 9th. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They issued an "outperform" rating and a $63.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, October 24th. JMP Securities restated a "market outperform" rating and set a $70.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $68.00 price target on shares of Jasper Therapeutics in a report on Monday, December 23rd.

Hedge Funds Weigh In On Jasper Therapeutics

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets grew its position in Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock valued at $47,000 after acquiring an additional 1,698 shares during the last quarter. Wolff Wiese Magana LLC purchased a new stake in shares of Jasper Therapeutics in the 3rd quarter valued at $59,000. MetLife Investment Management LLC grew its holdings in shares of Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock valued at $129,000 after purchasing an additional 3,873 shares during the last quarter. Rhumbline Advisers purchased a new position in Jasper Therapeutics in the 2nd quarter worth $300,000. Finally, Jane Street Group LLC bought a new stake in Jasper Therapeutics in the third quarter worth $251,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Price Performance

Shares of JSPR traded up $0.43 during midday trading on Wednesday, hitting $21.38. 286,329 shares of the company traded hands, compared to its average volume of 176,667. Jasper Therapeutics has a one year low of $6.41 and a one year high of $31.01. The firm has a market cap of $320.72 million, a P/E ratio of -4.51 and a beta of 2.18. The stock has a 50-day moving average of $22.05 and a 200-day moving average of $20.57.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.